Odes, Rachel
Alway, Jessica
Kushel, Margot
Max, Wendy
Vijayaraghavan, Maya
Funding for this research was provided by:
National Cancer Institute (5R37CA248448-02)
Article History
Received: 27 September 2022
Accepted: 23 October 2022
First Online: 14 November 2022
Declarations
:
: This study was approved by the University of California San Francisco Institutional Review Board (IRB number: 20–33214). The study was considered minimal risk, and does not require a data and safety monitoring board. Participation in this study is voluntary and all participants are provided with information about the study and have an opportunity to ask questions about the study prior to enrollment. Participants sign a consent document and are provided information about potential risks and benefits to participation and the anticipated time commitment. Participants are allowed to withdraw from the study at any time and for any reason. Protocol modifications will be submitted to the IRB for approval. The protocol is in its third version and was approved on July 5, 2022.
: This protocol paper does not contain any information about specific individuals. The study described in the paper will collect information about individuals, but any resulting published work will not identify them.
: The authors declare that they have no competing interests.